Search
TMC-310911
go.drugbank.com/drugs/DB15623Investigational[L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnMetamizole (dipyrone) is a pyrazolone derivative that belongs to the group of nonacid nonopioids. It is considered a potent analgesic and antipyretic with favourable gastrointestinal tolerability. Metamizole was formerly marketed in the ...
Ertiprotafib
go.drugbank.com/drugs/DB06521ExperimentalErtiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improv...
Troxacitabine
go.drugbank.com/drugs/DB04961InvestigationalTroxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnLeukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth musc...
MB07811
go.drugbank.com/drugs/DB05192InvestigationalMB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides.
Rocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalThe drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.
Tegoprazan
go.drugbank.com/drugs/DB16690InvestigationalTegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalThe vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.